List of Excipients in Branded Drug ZYDONE

« Back to Dashboard

Generic Drugs Containing ZYDONE

Company	Ingredient	NDC	Excipient
STAT RX USA LLC	hydrocodone bitartrate and acetaminophen	16590-350	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	hydrocodone bitartrate and acetaminophen	16590-350	CROSCARMELLOSE SODIUM
STAT RX USA LLC	hydrocodone bitartrate and acetaminophen	16590-350	CROSPOVIDONE

What are the Most Frequently-Used Excipients in ZYDONE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

Zydone Excipient Strategy and Commercial Opportunities

Last updated: November 6, 2026

Zydone is an immediate-release hydrocodone bitartrate/acetaminophen combination product. Its commercial opportunity is primarily in generic or reformulated hydrocodone/acetaminophen products, not in legacy-brand exclusivity. The strongest excipient strategy is a low-complexity, robust immediate-release tablet using common compendial materials, a 325 mg acetaminophen strength aligned with current FDA safety policy, and manufacturing controls that support rapid dissolution, content uniformity, and reliable supply.

The main constraints are opioid scheduling, acetaminophen hepatotoxicity risk, mature generic competition, limited brand value, and the absence of a clear commercial moat from conventional excipients alone.

What is Zydone and how is it positioned?

Zydone is a prescription combination of hydrocodone bitartrate and acetaminophen used for short-term management of moderate to moderately severe pain. Historical U.S. strengths included hydrocodone bitartrate 5 mg, 7.5 mg, or 10 mg combined with 400 mg acetaminophen. The product is an immediate-release oral tablet rather than an extended-release or abuse-deterrent formulation.

Attribute	Zydone
Active ingredients	Hydrocodone bitartrate and acetaminophen
Dosage form	Immediate-release tablet
Historical acetaminophen load	400 mg per tablet
Controlled-substance status	Schedule II opioid in the U.S.
Primary therapeutic use	Acute pain
Regulatory pathway for copies	ANDA, subject to reference-product requirements
Primary formulation challenge	Balancing opioid dose uniformity with high acetaminophen tablet loading
Principal safety issue	Opioid respiratory depression and acetaminophen-related liver injury

FDA directed sponsors of prescription combination products to limit acetaminophen to no more than 325 mg per dosage unit because higher amounts increase the risk of severe liver injury without providing a clinically meaningful benefit in most opioid combinations. This makes a 325 mg acetaminophen strength more commercially defensible than a 400 mg strength for a new product strategy (FDA, 2011).

What excipient strategy best fits a Zydone-equivalent tablet?

A Zydone-equivalent product should use a conventional immediate-release platform unless the sponsor has a defined clinical or regulatory reason to pursue abuse deterrence, modified release, or an alternative dosage form.

Recommended excipient architecture

Functional role	Preferred excipient classes	Strategic rationale
Diluent	Microcrystalline cellulose, dibasic calcium phosphate, lactose, or a combination	Supports tablet mass, flow, and compression
Binder	Povidone or pregelatinized starch	Improves granule strength and reduces friability
Disintegrant	Croscarmellose sodium, crospovidone, or sodium starch glycolate	Supports rapid tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, used at controlled concentration and blending time	Reduces tooling adhesion without materially slowing dissolution
Film coating	Hypromellose-based coating with titanium dioxide and permitted colorants	Improves identification, handling, and moisture protection
Opacifier or color system	Titanium dioxide or approved alternative, subject to jurisdictional requirements	Supports product differentiation and light protection

The preferred design is usually a direct-compression or dry-granulation process. Wet granulation can improve content uniformity and compressibility but adds drying, residual-moisture, and process-validation burdens.

Why content uniformity is a central issue

Hydrocodone is present at a low dose relative to acetaminophen. The formulation must distribute a small quantity of hydrocodone uniformly through a comparatively high-mass tablet. The risk is greatest when the active pharmaceutical ingredient has poor flow, broad particle-size distribution, electrostatic behavior, or a tendency to segregate from the diluent.

A robust process should use:

1. Controlled hydrocodone particle size.
2. Geometric dilution or a validated premix step.
3. Low-segregation transfer and hopper design.
4. In-process blend uniformity testing.
5. Weight and potency controls linked to compression speed.
6. Dissolution testing that detects lubricant overmixing or excessive compression force.

Excipient selection alone does not solve low-dose uniformity. The commercial value lies in the interaction between excipient grade, particle engineering, blending sequence, and compression process.

What acetaminophen strategy creates the strongest opportunity?

A 325 mg acetaminophen strength is the most practical development target for a new hydrocodone combination product. It aligns with FDA’s action limiting prescription combination products to 325 mg acetaminophen per dosage unit and may reduce physician and payer resistance relative to a legacy 400 mg or 500 mg configuration (FDA, 2011).

Commercially attractive strength options

Strength concept	Commercial assessment
Hydrocodone 5 mg / acetaminophen 325 mg	Broadest use case; suitable for lower-dose acute pain
Hydrocodone 7.5 mg / acetaminophen 325 mg	Useful for dose escalation while maintaining the FDA-aligned acetaminophen load
Hydrocodone 10 mg / acetaminophen 325 mg	Higher opioid exposure; greater clinical and managed-care scrutiny
Hydrocodone with 400 mg or 500 mg acetaminophen	Weak new-product proposition because of safety and regulatory history
Hydrocodone without acetaminophen	Potentially differentiated but would require a different regulatory and clinical positioning strategy

Reducing acetaminophen from 400 mg to 325 mg also gives sponsors a clearer product narrative: preserve hydrocodone analgesia while reducing cumulative acetaminophen exposure. That positioning does not remove the need for opioid-risk controls, but it addresses a recognized limitation of older combination products.

What formulations are protected by Zydone-related patents?

Conventional Zydone-type immediate-release tablets are unlikely to support a durable new patent position based only on standard excipients. Broad use of microcrystalline cellulose, povidone, crospovidone, croscarmellose sodium, starch, silica, and magnesium stearate is generally difficult to protect unless the claims require a specific composition range, manufacturing sequence, dissolution profile, or stability result.

Potentially protectable formulation areas include:

• A defined hydrocodone particle-size distribution.
• A segregationsuppressing premix or granulation process.
• A narrow excipient ratio that produces superior content uniformity.
• A tablet with a specified dissolution profile.
• A low-acetaminophen formulation with improved stability.
• An abuse-deterrent matrix or multiparticulate system.
• A tamper-resistant coating or extraction-limiting excipient system.
• A dosage form that reduces swallowing difficulty without altering opioid release.
• A formulation that improves stability under high humidity or elevated temperature.

A patent strategy based on formulation performance is stronger than one based solely on naming familiar excipients. Claims should connect the composition to measurable results, such as hydrocodone content uniformity, dissolution, crush resistance, extraction resistance, or shelf-life stability.

When does Zydone lose exclusivity?

Zydone is a legacy immediate-release opioid combination product. Its commercial exclusivity is not expected to be the main barrier to generic entry. The relevant U.S. barriers are FDA approval requirements, controlled-substance compliance, manufacturing capacity, supply-chain controls, and any currently listed patents associated with the reference product or an approved alternative formulation.

Exclusivity category	Zydone assessment
New chemical entity exclusivity	Not applicable to a legacy combination containing established active ingredients
Orphan exclusivity	Not applicable
Pediatric exclusivity	No established product-specific basis
Conventional formulation patent protection	Limited commercial significance unless an active patent is listed
Method-of-use protection	Potentially narrow and generally less important for an immediate-release acute-pain product
Generic substitution	Available where an approved therapeutically equivalent product exists
Controlled-substance compliance	Material operational barrier for manufacturers and distributors

The FDA Orange Book is the controlling source for current approved applications, therapeutic-equivalence evaluations, and listed patents. A commercial diligence review should distinguish between a live NDA, a discontinued NDA, an ANDA reference, and an actively marketed product. Orange Book listing status alone does not establish current brand sales or enforceable market power (FDA, 2024).

What is the Orange Book status of Zydone?

The relevant Orange Book questions are whether a current Zydone NDA remains listed, whether the product is actively marketed, whether patents are listed, and whether an ANDA applicant can rely on the product as a reference listed drug.

For an immediate-release hydrocodone/acetaminophen opportunity, the absence of a meaningful active patent estate would favor an ANDA or authorized-generic strategy. The regulatory risk would then shift from patent litigation to bioequivalence, opioid-control requirements, manufacturing inspection, and commercial access.

Paragraph IV challenge risk

A Paragraph IV certification would be relevant only if an ANDA applicant relies on a reference product with a listed patent. For a legacy immediate-release combination, the most likely scenarios are:

1. No active listed patent, permitting approval without a Paragraph IV dispute.
2. A formulation or method-of-use patent remains listed, creating a certification and litigation decision.
3. The applicant relies on a different reference product, making the Zydone brand less important to the regulatory strategy.
4. A 505(b)(2) sponsor pursues a differentiated dosage form and faces its own patent and exclusivity analysis.

The economic value of a Paragraph IV challenge would depend on the remaining patent term, projected market size, ANDA approval timing, litigation cost, and the number of competing applicants. Hatch-Waxman litigation is generally less attractive when the reference brand has low current sales and several therapeutically equivalent products already compete.

How strong is the patent estate for a Zydone reformulation?

The likely patent estate for a conventional Zydone reformulation is weak unless the sponsor creates a technically distinctive product.

Patent-strength assessment

Claim type	Relative strength	Main vulnerability
Standard tablet using common excipients	Low	Obviousness and routine formulation optimization
325 mg acetaminophen reformulation	Low to moderate	FDA-driven design choice may be predictable
Specific dissolution profile	Moderate	Requires credible unexpected performance
Low-dose hydrocodone uniformity process	Moderate	Stronger if supported by reproducible data
Abuse-deterrent formulation	Moderate to strong	Requires meaningful abuse-deterrence evidence and regulatory alignment
Novel multiparticulate or orally disintegrating system	Moderate	Clinical, stability, and manufacturing complexity
New hydrocodone salt or solid form	Potentially strong	Requires rigorous solid-state characterization and nonobviousness
Manufacturing process with reduced segregation	Moderate	Commercial value depends on scale-up and validation

A portfolio should combine composition claims, process claims, and performance-based claims. One narrow composition patent is unlikely to deter generic competition if a competitor can make the same product with a different excipient system.

What manufacturing and intellectual-property barriers exist?

The most significant manufacturing barriers are operational rather than proprietary.

Manufacturing barriers

• Low-dose hydrocodone content uniformity.
• Segregation during blending and transfer.
• Acetaminophen’s high mass fraction.
• Tablet capping, lamination, and friability at high compression speeds.
• Lubricant-related dissolution slowdown.
• Moisture sensitivity and stability during long-term storage.
• Controlled-substance inventory reconciliation.
• Secure handling, diversion prevention, and recordkeeping.
• DEA quota and distribution requirements.
• Serialization and traceability obligations.

Hydrocodone products are subject to the Controlled Substances Act and DEA requirements. A sponsor needs an authorized controlled-substance manufacturing and distribution structure before a commercial launch can scale (DEA, 2024).

Intellectual-property barriers

The strongest IP barriers would arise from:

• Abuse-deterrent technology.
• Controlled-release hydrocodone formulations.
• Novel delivery devices.
• New solid forms or salts.
• Pediatric or geriatric dosage forms with clinical differentiation.
• Proprietary manufacturing systems that materially improve uniformity or stability.

A basic immediate-release tablet has limited ability to generate exclusivity through excipients. The more defensible business model is often a platform approach that applies the same manufacturing technology to several opioid or nonopioid products.

What generic launch scenarios exist for Zydone?

Scenario 1: Standard ANDA launch

A sponsor develops an immediate-release hydrocodone/acetaminophen tablet that matches the reference product’s dosage form, strength, route, and release characteristics. The opportunity is relatively low risk technically but exposed to price erosion and multiple generic competitors.

Scenario 2: 325 mg acetaminophen repositioning

The sponsor develops hydrocodone/acetaminophen 325 mg tablets and positions the product around lower acetaminophen exposure. This may have stronger physician and payer acceptance than a legacy 400 mg product, although it does not guarantee premium pricing.

Scenario 3: Authorized-generic or contract-manufacturing supply

A manufacturer supplies an established pharmaceutical company, hospital group, or specialty distributor. The value is volume stability and lower commercial overhead rather than product differentiation.

Scenario 4: Abuse-deterrent product

A tamper-resistant tablet or multiparticulate product may support stronger pricing and institutional access. FDA expects abuse-deterrent labeling to be supported by category-specific studies, and abuse-deterrent properties do not prevent misuse or addiction (FDA, 2015).

Scenario 5: Alternative dosage form

An orally disintegrating, sprinkle, or lower-swallowing-burden product may address patients who have difficulty swallowing tablets. This route carries higher development and clinical risks and could trigger new patent and exclusivity opportunities.

Which companies are challenging Zydone?

The principal competitive threat is not necessarily a named Zydone challenger. It is the broader field of manufacturers selling hydrocodone/acetaminophen products, including large generic companies, specialty generic firms, and contract manufacturers.

Competition typically centers on:

• Unit price.
• Supply reliability.
• FDA inspection history.
• DEA compliance.
• Hospital and wholesaler contracts.
• Ability to maintain multiple strengths.
• Product availability during allocation periods.
• Formulary and pharmacy network access.

A company pursuing Zydone-related opportunities should benchmark against generic hydrocodone/acetaminophen products rather than against the historical Zydone brand alone.

What licensing deals could support a Zydone strategy?

The most relevant licensing structures are:

Deal type	Strategic use
Excipient license	Access to a proprietary taste-masking, abuse-deterrent, or stability technology
Manufacturing license	Transfer of a validated controlled-substance tablet process
505(b)(2) formulation license	Use of a differentiated dosage form or delivery platform
Authorized-generic agreement	Brand-sponsored supply under a separate commercial label
Regional commercialization license	Local distribution in markets where hydrocodone products are permitted
Contract-development agreement	Outsourced formulation, analytical, and regulatory support
Co-development agreement	Share investment in abuse-deterrent or modified-release technology

A licensing deal is more attractive when the technology solves a measurable problem: dose uniformity, extraction resistance, stability, adherence, or manufacturing yield. A license covering only a conventional excipient blend is unlikely to justify a substantial royalty.

What is the FDA regulatory status and biosimilar risk?

Zydone is a small-molecule drug, not a biologic. Biosimilar risk does not apply. The relevant regulatory route is an ANDA for a therapeutically equivalent generic or a 505(b)(2) application for a differentiated product that relies in part on FDA findings for an approved drug.

The core FDA requirements include:

• Pharmaceutical equivalence.
• Bioequivalence.
• Comparable dosage form and route.
• Validated analytical methods.
• Adequate stability data.
• Controlled-substance compliance.
• Current Good Manufacturing Practice compliance.
• Appropriate labeling and risk information.

An abuse-deterrent version may require additional comparative studies and cannot assume that conventional bioequivalence data alone will establish the desired labeling claims (FDA, 2015).

How does Zydone compare with other hydrocodone products?

Product category	Excipient opportunity	IP opportunity	Commercial outlook
Conventional immediate-release tablet	Low complexity, high process efficiency	Limited	Large but price-sensitive generic market
Lower-acetaminophen combination	Conventional tablet platform	Moderate if formulation or use is distinct	Better safety positioning
Extended-release hydrocodone	Complex release-control system	Stronger potential	Higher clinical and regulatory risk
Abuse-deterrent hydrocodone	Specialized matrix or coating	Stronger	Potential premium, but high development cost
Hydrocodone-only product	Lower acetaminophen exposure	Product and method claims possible	Different clinical positioning
Nonopioid acute-pain product	Standard or novel oral platform	Potentially stronger differentiation	Competes on safety and prescribing trends

What revenue exposure and commercial opportunity exist?

Zydone-specific revenue cannot be inferred from historical brand recognition. The commercial opportunity should be modeled from the broader hydrocodone/acetaminophen market, the number of approved competitors, average selling price, channel access, and controlled-substance allocation.

The most defensible revenue models are:

1. High-volume, low-margin generic supply.
2. Multi-strength institutional contracts.
3. Private-label or authorized-generic distribution.
4. Premium differentiated dosage forms.
5. Technology licensing to generic manufacturers.
6. Contract manufacturing for controlled-substance portfolios.

A conventional tablet has the lowest development risk but also the lowest pricing power. A differentiated formulation can improve margin, but the sponsor must support the product with clinical, abuse-deterrence, stability, or manufacturing data that competitors cannot easily replicate.

Key Takeaways

• Zydone is an immediate-release hydrocodone bitartrate/acetaminophen product with limited standalone brand exclusivity value.
• A new commercial strategy should favor 325 mg acetaminophen strengths over legacy higher-acetaminophen configurations.
• Common excipients can deliver a robust product, but they provide little patent protection by themselves.
• Low-dose hydrocodone content uniformity is the central formulation and manufacturing challenge.
• The strongest IP opportunities involve abuse deterrence, solid-state control, dissolution performance, alternative dosage forms, or validated low-segregation manufacturing.
• Generic competition, DEA compliance, FDA inspection readiness, and supply reliability are more important than brand recognition.
• Biosimilar risk does not apply because Zydone is a small-molecule product.
• The best licensing targets are technologies that improve extraction resistance, stability, dose uniformity, or manufacturing economics.

FAQs

Can a new Zydone product use the same excipients as the historical product?

Yes. Generic products may use the same or different inactive ingredients if they meet applicable FDA requirements, do not create safety concerns, and produce the required pharmaceutical and bioequivalence performance.

Is a 400 mg acetaminophen Zydone formulation commercially attractive?

It is less attractive for a new launch than a 325 mg formulation because FDA policy limits prescription combination products to 325 mg acetaminophen per dosage unit and the higher load creates a weaker safety profile.

Can excipients make a hydrocodone tablet abuse-deterrent?

Excipients can contribute to abuse-deterrent properties when incorporated into a validated formulation platform. A sponsor must support the relevant claims with FDA-recognized laboratory, pharmacokinetic, and abuse-potential data.

Would a Zydone reformulation qualify for new drug exclusivity?

Only a product meeting the statutory requirements for a qualifying new formulation, clinical investigation, or other recognized exclusivity category would receive new exclusivity. Routine excipient substitution generally does not create meaningful regulatory exclusivity.

What is the best commercial entry point for a small pharmaceutical company?

A focused 325 mg immediate-release product supplied through contract manufacturing, private label, or regional distribution is typically more practical than an independently marketed abuse-deterrent product. The latter requires substantially greater capital, regulatory evidence, and commercial infrastructure.

References

1. Drug Enforcement Administration. (2024). Controlled substances act and regulatory requirements. U.S. Department of Justice.

2. U.S. Food and Drug Administration. (2011). FDA drug safety communication: Prescription combination drug products with more than 325 mg of acetaminophen. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

5. National Library of Medicine. (n.d.). Zydone: Hydrocodone bitartrate and acetaminophen tablet labeling. DailyMed.